Insider Shareholders with Direct Ownership of Kiniksa Pharmaceuticals, Ltd. (KNSA)
This section provides a comprehensive overview of the insiders with direct ownership of Kiniksa Pharmaceuticals, Ltd. (KNSA). You can find detailed information about the size and nature of each insider's ownership stake, as well as the latest updates on their holdings.
Kiniksa Pharmaceuticals, Ltd. Insider List
Insider | Adquired | Disposed | Held | # of Trades | Last Transaction |
---|---|---|---|---|---|
Thomas W. Beetham
EVP & Chief Legal Officer |
300,000 | 2,477 | 297,523 $9.75 Million | 2 |
Feb 03, 2021
Reduced 0.83%
|
Sanj K Patel
CHAIRMAN & CEO |
649,382 | 557,348 | 96,674 $3.17 Million | 60 |
May 28, 2025
Reduced 39.12%
|
John F. Paolini
CHIEF MEDICAL OFFICER |
266,381 | 240,196 | 57,403 $1.88 Million | 50 |
Aug 06, 2025
Reduced 33.81%
|
Eben Tessari
CHIEF OPERATING OFFICER |
357,866 | 415,280 | 49,915 $1.64 Million | 68 |
Aug 05, 2025
Reduced 1.09%
|
Michael R Megna
CHIEF ACCOUNTING OFFICER |
154,893 | 123,435 | 33,041 $1.08 Million | 67 |
Aug 04, 2025
Reduced 33.97%
|
Mark Ragosa
CHIEF FINANCIAL OFFICER |
312,928 | 293,098 | 27,009 $885,355 | 72 |
Aug 04, 2025
Reduced 41.15%
|
18,474 | 0 | 18,474 $605,577 | 7 |
Jul 01, 2025
Added 5.62%
|
|
29,680 | 0 | 14,840 $486,455 | 1 |
Jun 06, 2019
Added 50.0%
|
|
12,546 | 0 | 12,546 $411,257 | 3 |
Jun 05, 2025
Added 20.19%
|
|
61,953 | 49,407 | 12,546 $411,257 | 11 |
Jun 11, 2025
Reduced 49.58%
|
|
190,315 | 177,769 | 12,546 $411,257 | 9 |
Aug 14, 2025
Reduced 86.18%
|
|
77,054 | 64,508 | 12,546 $411,257 | 5 |
Jul 30, 2025
Reduced 83.72%
|
|
12,546 | 0 | 12,546 $411,257 | 3 |
Jun 05, 2025
Added 20.19%
|
|
Ross Moat
CHIEF COMMERCIAL OFFICER |
229,159 | 225,030 | 9,415 $308,623 | 50 |
Jun 03, 2025
Reduced 74.56%
|
Qasim Rizvi
Chief Commercial Officer |
7,337 | 2,161 | 5,176 $169,669 | 2 |
Dec 31, 2020
Reduced 29.45%
|